Tongyu Y. Tong

No. 628 Zhenyuan Road
Shenzhen, 518107, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

PARP1-mediated PARylation of TEAD4 stabilizes the YAP1-TEAD4 complex and promotes growth and immune evasion in breast cancer cells.

PARP1-mediated PARylation of TEAD4 stabilizes the YAP1-TEAD4 complex and promotes growth and immune evasion in breast cancer cells.

Journal: Science signaling

Published: October 21, 2025

Targeting YAP1-CD70 axis potentiates the efficacy of anti-PD-1 therapy in prostate cancer.

Targeting YAP1-CD70 axis potentiates the efficacy of anti-PD-1 therapy in prostate cancer.

Journal: Biomarker research

Published: July 01, 2025

CDK12-Mediated Phosphorylation of FOXA1 Promotes Prostate Cancer Progression via the MDM2-p53 Axis.

CDK12-Mediated Phosphorylation of FOXA1 Promotes Prostate Cancer Progression via the MDM2-p53 Axis.

Journal: Research (Washington, D.C.)

Published: May 04, 2025

CDK12 Inactivation Attenuates Prostate Cancer Progression by Inhibiting BNIP3-Mediated Mitophagy.

CDK12 Inactivation Attenuates Prostate Cancer Progression by Inhibiting BNIP3-Mediated Mitophagy.

Journal: Cell proliferation

Published: March 04, 2025

A cross-sectional study examining the relationship between the advanced lung cancer inflammation index and prostate cancer.

A cross-sectional study examining the relationship between the advanced lung cancer inflammation index and prostate cancer.

Journal: Journal of health, population, and nutrition

Published: February 27, 2025

HOMER3 orchestrates SRC-YAP1 activity that promotes tumor cell growth and antagonizes anti-tumor immunotherapy in prostate cancer.

HOMER3 orchestrates SRC-YAP1 activity that promotes tumor cell growth and antagonizes anti-tumor immunotherapy in prostate cancer.

Journal: Oncogene

Published: February 13, 2025

TGF-β3 promotes vascular normalization of prostate cancer to potentiate immunotherapy and chemotherapy.

TGF-β3 promotes vascular normalization of prostate cancer to potentiate immunotherapy and chemotherapy.

Journal: Cancer immunology, immunotherapy : CII

Published: November 26, 2024

Causal relationships between plasma metabolites and prostate cancer: A Mendelian randomization study exploring immune and inflammatory mediators.

Causal relationships between plasma metabolites and prostate cancer: A Mendelian randomization study exploring immune and inflammatory mediators.

Journal: Current urology

Published: October 12, 2024

Acidity-Actuated Polymer/Calcium Phosphate Hybrid Nanomotor (PCaPmotor) for Penetrating Drug Delivery and Synergistic Anticancer Immunotherapy.

Acidity-Actuated Polymer/Calcium Phosphate Hybrid Nanomotor (PCaPmotor) for Penetrating Drug Delivery and Synergistic Anticancer Immunotherapy.

Journal: Nano letters

Published: August 26, 2024

Hippo signaling modulation and its biological implications in urological malignancies.

Hippo signaling modulation and its biological implications in urological malignancies.

Journal: Molecular aspects of medicine

Published: December 19, 2023

ROS-driven supramolecular nanoparticles exhibiting efficient drug delivery for chemo/Chemodynamic combination therapy for Cancer treatment.

ROS-driven supramolecular nanoparticles exhibiting efficient drug delivery for chemo/Chemodynamic combination therapy for Cancer treatment.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: September 16, 2023

New insights into the ambivalent role of YAP/TAZ in human cancers.

New insights into the ambivalent role of YAP/TAZ in human cancers.

Journal: Journal of experimental & clinical cancer research : CR

Published: January 17, 2023

Showing 1-12 of 22

Last Updated: 09/26/2026